Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|HER2/Neu Negative|Invasive Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Talazoparib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)